Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01568697
Other study ID # 120100
Secondary ID 12-D-0100
Status Recruiting
Phase
First received
Last updated
Start date October 5, 2012

Study information

Verified date April 10, 2024
Source National Institutes of Health Clinical Center (CC)
Contact Laurie D Brenchley, R.D.H.
Phone (301) 451-2551
Email laurie.brenchley@nih.gov
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: - Gum disease is a condition in which the tissue around the tooth root becomes swollen and infected. This condition can cause tooth loss if it is not treated. Who gets gum disease and how bad it will be depends on (1) the different bacteria in the mouth and (2) how the immune system of an individual handles these bacteria. Researchers want to look at the oral bacteria and genetic immune problems of different people to learn how these affect gum disease and other conditions of the mouth. Objectives: - To study how immune system problems may lead to problems in the mouth, including gum disease. Eligibility: - Children and adults at least 7 years of age who have genetic problems with their immune system. - Healthy adults that have periodontal disease - Health adults that do not have periodontal disease Design: - This study will involve a screening visit and a study visit. - Participants will be screened with a medical history, blood work and a full oral and dental exam, including dental x-rays and photos. - The study visit will involve collection of blood, urine, and other samples, including saliva, plaque, and gum swabs. Any abnormal tissue will sampled for a biopsy. Additional oral and dental exams will be performed. Participants will also answer questions about any current medical or dental problems.


Description:

This is a cross sectional/natural history protocol designed to investigate the clinical, microbiologic, and immunologic consequences of genetic immune defects in the oral cavity. The hypothesis is that genetic immune defects will lead to alterations in the local immune response and microbial colonization and ultimately predispose to susceptibility to oral infections and inflammatory conditions. In the cross-sectional phase the following individuals will be enrolled, evaluated and screened for presence and severity of periodontitis, presence of a genetic defects and sampled for studies in oral immunity and microbiome: 1) individuals diagnosed with genetic immune defects 2) individuals with severe periodontitis of suspected genetic etiology and their family members 3) healthy volunteers. Subjects identified with a genetic immune defect and with presence of oral disease (primarily periodontitis) may enter the natural history phase of the study to be clinically followed at the National Institutes of Health (NIH) over time. This protocol aims to determine whether specific genetic immune defects will predispose to oral disease (primarily periodontitis) and to better understand consequences of immune deficiency on the oral immune response and microbiome. Primary Objectives 1. Investigate the degree, scope, etiology and natural history of oral manifestations in patients with genetic immune defects. 2. Characterize the immune response in the oral cavity of patients with genetic immune defects. 3. Characterize the microbiome in the oral cavity of patients with genetic immune defects. Secondary Objectives 1. Assay development/validation for the study of tissue immunity and microbiome characterization 2. Establishment of normative values for immune mediators and microbial elements at the oral cavity Study Population (s) The study population will include: 1. Subjects with genetic immune defects 2. Subjects with severe periodontitis of suspected genetic etiology and their family members 3. Healthy volunteers (with/without periodontal disease) Design This is a cross-sectional/natural history study for the evaluation of clinical, immunologic, and microbiologic oral manifestations (primarily periodontitis) in patients diagnosed with genetic immune defects or those with severe periodontitis of suspected genetic etiology and healthy volunteer subjects. Cross Sectional Phase: Three groups of subjects will be enrolled in the cross-sectional phase of the study 1) individuals diagnosed with genetic immune defects 2) individuals with severe periodontitis of suspected genetic etiology and their family members that include parents or siblings 3) healthy volunteers (with/without periodontal disease). All groups will be evaluated for oral disease (periodontitis) and sampled for oral immunity, systemic immunity and microbiome characterization. Individuals with severe periodontitis in the presence/absence of a genetic defect may be offered the option of receiving standard of care inflammatory control periodontal treatment at NIH without travel compensation, following the cross-sectional portion of the study. Family members (parents or siblings) of individuals with periodontal disease of suspected genetic may be asked to participate in this study. During the course of genetic testing, family members may be enrolled in the cross sectional phase of the study for phenotyping and genetic testing. Natural History Phase: Subjects identified with a genetic defect with the presence of oral disease may enroll in the natural history phase of the study to be followed clinically over time. Primary Outcome Measures 1. Clinical intraoral characterization (i.e., presence and severity of periodontitis). 2. Characterize the immune response in the oral cavity of patients with genetic immune defects 3. Characterize the microbiome in the oral cavity of patients with genetic immune defects Secondary Outcome Measures 1. Assay development/validation for the study of tissue immunity and microbiome characterization 2. Establishment of normative values for immune mediators and microbial elements at the oral cavity Exploratory Outcome Measures Initial data from this study may generate new hypotheses for investigation as part of this study.


Recruitment information / eligibility

Status Recruiting
Enrollment 700
Est. completion date
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 7 Years and older
Eligibility - INCLUSION CRITERIA: Subjects with Genetic Immune Defects: Patients with a known genetic immune defect will be eligible for screening inclusion under this protocol. - Diagnosed with a genetic immune defect - Willing to allow genetic testing - 7 years old Subjects with Severe Periodontitis of Suspected Genetic Etiology: - History of severe periodontitis prior to age <30 - Willing to allow genetic testing ->=7 years old - In good general health Family members of Subjects with Severe Periodontitis of Suspected Genetic Etiology: -Willing to allow genetic testing ->=7 years old Healthy Volunteer Subjects (with/without periodontitis): - In good general health ->=18 years old - Willing to allow genetic testing - Have a minimum of 20 natural teeth Inclusion Criteria for Natural History phase, all subjects: - Diagnosis of genetic immune defect - Presence of oral manifestation (primarily periodontitis) Criteria for standard of care treatment: - Active untreated disease (visible signs of tissue inflammation including erythema/edema, generalized bleeding upon probing) - Periodontal disease defined as bone loss of >=5mm as measured on periodontal exam. EXCLUSION CRITERIA: All Subjects: - History of Hepatitis B or C - History of HIV - Prior radiation therapy to the head or neck - Have an active malignancy except localized basal or squamous cell carcinoma of the skin - Have been treated with systemic chemotherapeutics or radiation therapy within 5 years of screening - Pregnant or lactating - If participation in the protocol would not be safe or in the subject s best interest in the opinion of either the PI or the primary medical team. Additional Exclusions for Healthy Volunteers: - Diagnosis of diabetes and/or HbA1C level >6% - More than 3 hospitalizations in the last 3years - Have an autoimmune disorder such as Lupus, Rheumatoid arthritis, etc. - In the 3 months before study enrollment, have used any of the following: - Systemic (intravenous, intramuscular, or oral) antibiotics - Oral, intravenous, intramuscular, intranasal, or inhaled corticosteroids or other immunosuppressants (e.g., cyclosporine) - Cytokine therapy - Methotrexate or immunosuppressive chemotherapeutic agents - Large doses of commercial probiotics (>=10^8 colony-forming units or organisms per day); includes tablets, capsules, lozenges, chewing gum, or powders in which a probiotic is a primary component; ordinary dietary components such as fermented beverages/milks, yogurts, and foods do not apply - Have used tobacco products (including e-cigarettes) within 1 year of screening - Unwillingness to consent to oral biopsy - NIH employees working in the Oral Immunity and Inflammation Unit and members of the Clinical Research Core Team will not be eligible for enrollment. Additional Exclusions for Standard of Care Treatment at NIH: - Mild/moderate non-active disease (absence of active inflammatory lesions) - Subjects with urgent/complex restorative needs (ex. severe active carious lesions/fractured dentition) - Subjects in need for advanced prosthetic needs (including implants and restorations)

Study Design


Locations

Country Name City State
United States National Institutes of Health Clinical Center Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Dental and Craniofacial Research (NIDCR)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Maslowski KM, Mackay CR. Diet, gut microbiota and immune responses. Nat Immunol. 2011 Jan;12(1):5-9. doi: 10.1038/ni0111-5. — View Citation

Novak N, Haberstok J, Bieber T, Allam JP. The immune privilege of the oral mucosa. Trends Mol Med. 2008 May;14(5):191-8. doi: 10.1016/j.molmed.2008.03.001. Epub 2008 Apr 7. — View Citation

Rescigno M. The intestinal epithelial barrier in the control of homeostasis and immunity. Trends Immunol. 2011 Jun;32(6):256-64. doi: 10.1016/j.it.2011.04.003. Epub 2011 May 11. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary 1. Clinical intraoral characterization (i.e., presence and severity of periodontitis). The primary clinical endpoints of the study are severity and types of oral disease: specifically for periodontal disease, mean PD, mean CAL, proportion of sites with PD >5 mm, and proportion of subjects with BOP, proportion of patient with other inflammatory conditions or infections of the oral cavity by immune disorder.Characterization of the oral microbiome in patients with monogenic immune defects. Immunologic endpoints: types and levels of immune mediators in the saliva, GCF, oral tissues, and/or blood. 15 years
Primary 2. Characterize the immune response in the oral cavity of patients with genetic immune defects The primary clinical endpoints of the study are severity and types of oral disease: specifically for periodontal disease, mean PD, mean CAL, proportion of sites with PD >5 mm, and proportion of subjects with BOP, proportion of patient with other inflammatory conditions or infections of the oral cavity by immune disorder.Characterization of the oral microbiome in patients with monogenic immune defects. Immunologic endpoints: types and levels of immune mediators in the saliva, GCF, oral tissues, and/or blood. 15 years
Primary 3. Characterize the microbiome in the oral cavity of patients with genetic immune defects The primary clinical endpoints of the study are severity and types of oral disease: specifically for periodontal disease, mean PD, mean CAL, proportion of sites with PD >5 mm, and proportion of subjects with BOP, proportion of patient with other inflammatory conditions or infections of the oral cavity by immune disorder.Characterization of the oral microbiome in patients with monogenic immune defects. Immunologic endpoints: types and levels of immune mediators in the saliva, GCF, oral tissues, and/or blood. 15 years
Secondary 1. Assay development/validation for the study of tissue immunity and microbiome characterization Validate methodologies for measuring levels of immune mediators in oral fluids - Establish normative values of immune mediators in oral fluids and tissues - Assay development; Develop new methodologies to study pathways of the immune response in the oral cavity - Assay development: Develop new methodologies to study the microbiome in the oral cavity 15 years
Secondary 2. Establishment of normative values for immune mediators and microbial elements at the oral cavity Validate methodologies for measuring levels of immune mediators in oral fluids - Establish normative values of immune mediators in oral fluids and tissues - Assay development; Develop new methodologies to study pathways of the immune response in the oral cavity - Assay development: Develop new methodologies to study the microbiome in the oral cavity 15 years
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1